BrainStorm Cell Therapeutics Inc. reported its financial results for the third quarter ended September 30, 2025. Cash, cash equivalents, and restricted cash were approximately $0.2 million as of September 30, 2025. Research and development expenditures, net, were $0.9 million, down from $1.0 million in the same period in 2024. General and administrative expenses were $1.1 million, compared to $2.0 million for the third quarter of 2024. Net loss for the quarter was $2.1 million, compared to $2.7 million in the prior year, with net loss per share at $0.19, down from $0.51. The company is preparing to initiate a Phase 3b study of NurOwn for ALS, following FDA clearance of the planned clinical study.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN24801) on November 14, 2025, and is solely responsible for the information contained therein.